Mirador Capital Partners LP Has $1.27 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mirador Capital Partners LP raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,723 shares of the biopharmaceutical company’s stock after buying an additional 528 shares during the period. Mirador Capital Partners LP’s holdings in Gilead Sciences were worth $1,268,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Cedar Wealth Management LLC raised its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $43,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 453,734 shares of company stock valued at $41,902,086. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $92.12 on Thursday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The firm has a fifty day simple moving average of $91.96 and a 200 day simple moving average of $83.69. The stock has a market capitalization of $114.81 billion, a price-to-earnings ratio of 1,023.56, a PEG ratio of 1.27 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. UBS Group boosted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Mizuho boosted their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.